{"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"tb-500-glp1-gut","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-gut/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/tb-500-glp1-gut/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-gut/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-gut/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-gut/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-gut/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/tb-500-glp1-gut/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"tb-500-glp1-gut","title":"TB-500 for GLP-1 Gut Damage and Gastroparesis: What the Evidence Shows","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-07-17T02:42:14.998Z","body_excerpt":"## What's breaking down if you have GLP-1 gut damage / gastroparesis\n\nGLP-1 receptor agonists slow gastric emptying as part of their intended action on gut motility. In some people this effect becomes pronounced and persistent, producing symptoms that overlap with gastroparesis. The core issue is delayed stomach emptying that can lead to nausea, bloating, early satiety, and in rarer cases more serious motility problems.\n\nRepair-versus-degeneration framing applies here. The drug suppresses a motility signal to achieve metabolic benefits. When that suppression outruns the gut's ability to maintain normal function or recover normal motility, the problem persists. No direct tissue destruction occurs in most cases, but prolonged slowed transit can stress the enteric nervous system and smooth muscle layers that coordinate emptying.\n\n## Why TB-500 might help you\n\n1. You are reading about GLP-1 gut damage / gastroparesis — what breaks down matters before any compound name.\n2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf GLP-1 agonist use has left gut motility slowed and local repair processes lagging, the logic chain points to whether actin-based cell movement can be supported. TB-500 fragments of thymosin beta-4 bind actin and are studied in preclinical models for promoting cell migration to sites of tissue stress. That migration step is one of the early requirements for clearing stalled inflammatory signals and allowing structural reorganization of smooth muscle or mucosal layers.\n\nThe if-then is narrow: only if actin disorganization or failed cell recruitment is contributing to your specific motility lag would this pathway be relevant. It does not reverse the GLP-1 receptor signal itself.\n\n## Why GLP-1 agonists (class) matters for you\n\nGLP-1 agonists (class) support metabolism by enhancing insulin response, slowing gastric emptying, and reducing appetite. The same motility slowing that aids glycemic control and weight loss can trade off against normal gut transit in susceptible individuals. This is suppression of a signal rather than reduction of mechanical load. The metabolic support is the primary benefit; any gut slowing is a known mechanism-based effect that usually attenuates but can persist or intensify in some users. For someone already experiencing gastroparesis-like symptoms, the tradeoff is direct: continued use maintains the metabolic benefit while the motility signal remains suppressed.\n\n## How these fit together\n\nSingle-compound focus — TB-500 targets inflammation clearance / repair-cell migration. GLP-1 agonists provide metabolic support at the cost of motility suppression. The two do not directly interact in studied pathways; one addresses downstream repair questions while the other maintains the upstream metabolic change. Any combined discussion stays at the level of separate layers rather than claimed synergy.\n\n## What the evidence actually shows\n\nHuman data on TB-500 or thymosin beta-4 for gut motility or gastroparesis is absent. Scoping reviews of thymosin beta-4 and TB-500 map evidence primarily to wound healing, ocular repair, and vascular contexts, with human trials concentrated in skin/soft tissue and cornea settings (source s10). No included human studies address intestinal smooth muscle or enteric repair.\n\nPreclinical (mostly rodent and cell) work shows thymosin beta-4 promotes cell migration via actin sequestration and supports angiogenesis and reduced fibrosis in various tissues. These findings remain animal or in-vitro and do not establish translation to human GLP-1-related gastroparesis.\n\nGLP-1 agonist effects on gastric emptying are d","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c2","text":"GLP-1 agonists reproducibly delay gastric emptying in humans as a class effect.","tier":"human","weight":0.8,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s0","s1","s3"],"source_status":"sourced","why_material":"Documents the mechanistic suppression relevant to the reader's condition.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c3","text":"No human trials exist for TB-500 or thymosin beta-4 in gastroparesis or GLP-1 gut damage.","tier":"human","weight":0.8,"section":"What we do not know","slot":null,"interaction_risk":false,"status":"active","source_ids":["s10"],"source_status":"sourced","why_material":"Highlights the absence of direct evidence.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c1","text":"Thymosin beta-4 / TB-500 evidence is largely preclinical with human data limited to wound/skin and ocular contexts.","tier":"preclinical","weight":0.5,"section":"What the evidence actually shows","slot":null,"interaction_risk":false,"status":"active","source_ids":["s10"],"source_status":"sourced","why_material":"Establishes tier separation between animal and human data for gut applications.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c4","text":"Reddit users discuss TB-500 mainly in general recovery stacks rather than specific GLP-1 gastroparesis reversal.","tier":"anecdotal","weight":0.3,"section":"What people say on Reddit","slot":null,"interaction_risk":false,"status":"active","source_ids":["s29"],"source_status":"sourced","why_material":"Separates community reports from controlled data.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s10","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review","quote":"The evidence base was weighted toward mixed and in vitro designs... Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study.","summary":"2026 scoping review mapping 80 studies; confirms limited human data outside skin/eye and absence of gut-specific trials.","claim_ids":["c1","c3"],"link_status":"http_403","quote_status":"unverified","hash":"d4ae7fb9414932a075d266ea69533b0df4b0ea6d992724af0edfcc4d064178c7"},{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11620716/","title":"GLP-1 receptor agonists and delayed gastric emptying","quote":"This paper explores the intricate connection between GLP-1 and delayed gastric emptying, specifically gastroparesis.","summary":"Review of mechanisms linking GLP-1 agonism to gastroparesis symptoms in humans.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"833b961891176fbc84beb49d2bf6fe9b15f58eb47e72893c970409b72bbedfd9"},{"id":"s1","type":"review","url":"https://academic.oup.com/jcem/article/110/1/1/7824836","title":"Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide","quote":"While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through...","summary":"Documents human clinical consequences of motility slowing.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"96ef0beb455afdef0354182c11ca058d2604bf4af7dc700de4abd8bca7652a81"},{"id":"s3","type":"other","url":"https://www.fellahealth.com/guide/incidence-of-gastroparesis-with-glp-1","title":"Incidence of Gastroparesis with GLP-1 Medications","quote":"GLP-1 receptor agonists intentionally slow gastric emptying as part of their therapeutic mechanism...","summary":"Summarizes mechanistic and incidence data in humans.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"d2ccf63098a3aff5aef0be09f00b66a05e364c380c2af5b77c9231fd38774c12"},{"id":"s29","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1b7mwv8/how_many_of_you_have_experienced_permanent/","title":"How many of you have experienced permanent intestinal...","quote":"There is a glp-1 protein drink by Biocare that contains enzymes. Perhaps my story is not unique then?","summary":"Example of GLP-1 gut discussion on Reddit with limited peptide specificity.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"ff15e639b1dd791c49c2531bcc099a891d29e2f26e07386194140c673d44358d"}],"anecdotal_sources":[{"id":"s29","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1b7mwv8/how_many_of_you_have_experienced_permanent/","title":"How many of you have experienced permanent intestinal...","quote":"There is a glp-1 protein drink by Biocare that contains enzymes. Perhaps my story is not unique then?","summary":"Example of GLP-1 gut discussion on Reddit with limited peptide specificity.","claim_ids":["c4"],"link_status":"ok","quote_status":"unverified","hash":"ff15e639b1dd791c49c2531bcc099a891d29e2f26e07386194140c673d44358d"}],"scientific_sources":[{"id":"s10","type":"review","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review","quote":"The evidence base was weighted toward mixed and in vitro designs... Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study.","summary":"2026 scoping review mapping 80 studies; confirms limited human data outside skin/eye and absence of gut-specific trials.","claim_ids":["c1","c3"],"link_status":"http_403","quote_status":"unverified","hash":"d4ae7fb9414932a075d266ea69533b0df4b0ea6d992724af0edfcc4d064178c7"},{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11620716/","title":"GLP-1 receptor agonists and delayed gastric emptying","quote":"This paper explores the intricate connection between GLP-1 and delayed gastric emptying, specifically gastroparesis.","summary":"Review of mechanisms linking GLP-1 agonism to gastroparesis symptoms in humans.","claim_ids":["c2"],"link_status":"ok","quote_status":"unverified","hash":"833b961891176fbc84beb49d2bf6fe9b15f58eb47e72893c970409b72bbedfd9"},{"id":"s1","type":"review","url":"https://academic.oup.com/jcem/article/110/1/1/7824836","title":"Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide","quote":"While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through...","summary":"Documents human clinical consequences of motility slowing.","claim_ids":["c2"],"link_status":"http_403","quote_status":"unverified","hash":"96ef0beb455afdef0354182c11ca058d2604bf4af7dc700de4abd8bca7652a81"}],"user_reports":[],"related_articles":[],"question_graph":{"slug":"tb-500-glp1-gut","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":4,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":4,"claims_total":4,"sources":5,"anecdotal":1,"scientific":3,"user_reports":0,"questions":0,"evidence_ingests":0}}